ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2–expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177 Lu somatostatin analogue (SSA) therapy: Initial safety analysis.
- Resource Type
- Article
- Authors
- Morris, Michael; Ulaner, Gary A.; Halperin, Daniel M.; Strosberg, Jonathan R.; Mehr, Samuel H.; Li, Daneng; Soares, Heloisa P.; Anthony, Lowell Brian; Kotiah, Sandy Diana; Jacene, Heather; Pavel, Marianne E.; Kunz, Pamela L.; Ferreira, Denis Vasconcelos; Li, Joanne; Ma, Kimberly; Rearden, Jessica; Moran, Susan; Hope, Thomas A.; Singh, Simron
- Source
- Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p4132-4132, 1p
- Subject
- Language
- ISSN
- 0732183X